A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

HEPATOCELLULAR CARCINOMA Clinical Trial

Official title:

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00423306
• Other study ID #: SGL2005
• Status: Active, not recruiting
• Phase: Phase 2
• First received: January 16, 2007
• Last updated: November 13, 2013
• Start date: January 2007
• Est. completion date: December 2013

Study information

• Verified date: November 2013
• Source: Ziopharm
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. HCC diagnosed by histology or clinical evidence supported by liver mass(es) at least 2cm in the longest diameter and AFP equal to or more than 500 ng/mL in cirrhosis or chronic HBV or HCV infection27.

2. Male or female patients = 18 years of age

3. Patients who have a life expectancy of at least 12 weeks

4. Patients who have at least one uni-dimensional measurable lesion by CT-scan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST).

5. Patients who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0 - 2 (see Appendix 4).

6. Patients who have received local therapy, such as surgery, radiation therapy, hepatic arterial embolization, chemo-embolization, radio-frequency ablation or cryo-ablation are eligible, provided that they either have a target lesion which has not been subjected to local therapy and/or the target lesion(s) within the field of the local therapy has shown an increase of = 25% in the size. Furthermore, the local therapy applied to target or non-target lesions needs to have been completed at least 8 weeks prior to study inclusion. Lesions treated with external beam radiation therapy are not acceptable as target lesions, unless they fulfil the conditions described above.

7. No more than one prior chemotherapy based regimen is allowed. Patients can receive up to two regimes where target therapies have been used (washout)

8. Cirrhotic status of Child-Pugh Class A or B only (Appendix 5).

9. Adequate hepatic function at screening as assessed by the following:

• Platelet count = 60 x 109/L

• Hemoglobin = 8.5 g/dl

• Total bilirubin = 3 mg/dl

• ALT and AST = 5 x upper limit of normal

• Serum creatinine = 2.0 x the upper limit of normal

• PT-INR = 2.3 or PT = 6 seconds above control

10. Patients who give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

Exclusion Criteria

1. Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)

2. Congestive heart failure > NYHA Class II

3. Cardiac arrhythmias requiring anti-arrythmics (excluding beta blockers or digoxin for chronic stable atrial fibrillation) or QTc greater than 450 msec.

4. Active coronary artery disease or cardiac ischemia

5. Active clinically serious bacterial, viral or fungal infections (> grade 2 NCI-CTCAE, Version 3)

6. Known history of human immunodeficiency virus (HIV) infection for less than 2 years or uncontrolled disease on antiretroviral medication

7. Metastatic brain or meningeal tumors

8. Patients with seizure disorder requiring medication (such as anti-epileptics)

9. History of confusion or dementia or neurological condition that could mask a potential adverse response to the study drug (or something along these lines)

10. History of organ allograft

11. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results

12. Known or suspected allergy to the investigational agent or any agent given in association with this trial

13. Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study

14. Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 14 days prior to the start of study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• HEPATOCELLULAR CARCINOMA

Intervention

Drug:
• Darinaparsin
420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Ziopharm

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate		6 months	No
Secondary	Survival (overall and progression free)		6 months	Yes
Secondary	toxicities		6 months	Yes